Could this drug stop the body from turning muscle into bone?
NCT ID NCT06508021
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 25 times
Summary
This study tests an experimental drug called andecaliximab in 92 children and adults with fibrodysplasia ossificans progressiva (FOP), a rare disease where soft tissues turn into bone. The goal is to see if the drug safely reduces new abnormal bone growth and flare-ups. Participants receive either the drug or a placebo, with an option to continue on the drug afterward.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBRODYSPLASIA OSSIFICANS PROGRESSIVA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
University of California San Francisco (UCSF)
San Francisco, California, 94143, United States
-
University of Pennsylvania - Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.